Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 333 participants.

Also called NCT03624881

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 333 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03624881
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03624881. Allocation not applicable; no masking; primary purpose treatment. Start 2018-09-04 (actual); primary completion 2021-06-28 (actual). Results posted on 2022-09-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)
Condition
Paroxysmal Atrial Fibrillation
Intervention (Device)
Catheter ablation with EPU
Lead sponsor
Biosense Webster, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03624881
Content hash
ceecf1566c65a59d301fb036f9cf09ebefe7a7741ef63c82ce7fac1990212c42